Prognostic factors in polyarteritis Nodosa and Churg-Strauss syndrome: A prospective study in 342 patients

Medicine

Volumn 75, Issue 1, 1996, Pages 17-28

  Guillevin, Loïc ^a   Lhote, François ^a   Gayraud, Martine ^a   Cohen, Pascal ^a   Jarrousse, Bernard ^a   Lortholary, Olivier ^a   Thibult, Nadine ^b   Casassus, Philippe ^a,b  

^a UNIVERSITÉ PARIS 13   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CYCLOPHOSPHAMIDE; DAPSONE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; METHYLPREDNISOLONE; PREDNISONE; VIDARABINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHURG STRAUSS SYNDROME; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; HEPATITIS B; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; POLYARTERITIS NODOSA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CHURG-STRAUSS SYNDROME; CLINICAL PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HEPATITIS B; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PLASMA EXCHANGE; POLYARTERITIS NODOSA; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; VIDARABINE;

EID: 0030070089     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-199601000-00003     Document Type: Article

References (46)

1. Abu-Shakra M, Smythe H, Lewtas J, Badley E, Weber D, Keystone E. Outcome of polyarteritis nodosa and Churg-Strauss syndrome. Arthritis Rheum 37: 1798-1803, 1994.
2. Arkin A. A clinical and pathological study of polyarteritis nodosa. Am J Pathol 6: 401-2, 1930.
3. Bacon PA. Systemic vasculitic syndromes. Curr Opin Rheumatol 5: 5-10, 1993.
4. Blidi M, Nguyen Quang T, Cassan P, Guillevin L. Les cholécystites aigues de la périartérite noueuse. Huit observations. Ann Méd Interne (Paris) (in press), 1996.
5. Bron K, Strott C, Shapiro A. The diagnostic value of angiographic observations in polyarteritis nodosa. A case of multiple aneurysms in the visceral organs. Arch Intern Med 116: 450-54, 1983.
6. Cacoub P, Le TH, Guillevin L, Godeau P. Causes de décès dans les vascularites systémiques du groupe de la périartérite noueuse. Analyse d'une série de 165 patients. Ann Méd Interne (Paris) 139: 381-90, 1988.
7. Churg J. Nomenclature of vasculitic syndromes: A historical perspective. Am J Kidney Dis 18: 148-53, 1991.
8. Cohen R, Conn D, Ilstrup D. Clinical features, prognosis and response to treatment in polyarteritis. Mayo Clin Proc 55: 146-55, 1980.
9. Cupps T, Fauci A. Systemic necrotizing vasculitis. In: Smith LH Jr, ed. The vasculitides. Vol. XXI, Major problems in internal medicine. Philadelphia: WB Saunders, 1981.
10. Davson J, Ball J, Platt R. The kidney in periarteritis nodosa. Q J Med 17: 175-202, 1948.
11. Fauci AS, Haynes B, Katz P. The spectrum of vasculitis: Clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 89: 660-76, 1978.
12. Fauci A, Katz P, Haynes B, Wolff S. Cyclophosphamide therapy of severe necrotizing vasculitis. N Eng J Med 301: 235-38, 1979.
13. Finan MC, Winkelmann RK. The cutaneous extravascular necrotizing granuloma (Churg-Strauss granuloma) and systemic disease: A review of 27 cases. Medicine (Baltimore) 62: 142-58, 1983.
14. Fort JG, Abruzzo JL. Reversal of progressive necrotizing vasculitis with intravenous pulse cyclophosphamide and methylprednisolone. Arthritis Rheum 31: 1194-98, 1988.
15. Fortin P, Larson M, Watters A, Yeadon C, Choquette D, Esdaile J. Prognostic factors in systemic necrotizing vasculitis of the polyarteritis nodosa group. A review of 45 cases. J Rheumatol 22: 78-84, 1995.
16. Frohnert P, Sheps S. Long term follow-up study of polyarteritis nodosa. Am J Med 48: 8-14, 1967.
17. Gayraud M, Le Clercq P, Guillevin L. Treatment of good prognosis polyarteritis nodosa and Churg-Strauss syndrome: Comparison of steroids and two cyclophosphamide regimens (daily oral or monthly pulses) in 25 patients [abstract]. Arthritis Rheum 37: S 352, 1994.
18. Geffriaud RC, Noël LH, Chauveau D, Houhou S, Grunfeld JP, Lesavre P. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 39: 125-36, 1993.
19. Guillevin L, Fain O, Lhote F, Jarrousse B, Le THD, Bussel A, Leon A. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum 35: 208-15, 1992.
20. Guillevin L, Jarrousse B, Lok C, Lhote F, Jaïs JP, Le THD, Bussel A. Longterm follow-up after treatment of polyarteritis nodosa and ChurgStrauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 18: 567-74, 1991.
21. Guillevin L, Le THD, Godeau P, Jaïs P, Wechsler B. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: A study in 165 patients. Br J Rheumatol 27: 258-64, 1988.
22. Guillevin L, Lhote F. Distinguishing polyarteritis nodosa from microscopic polyangiitis and implications for treatment. Curr Opin Rheumatol 7: 20-24, 1995.
23. Guillevin L, Lhote F, Cohen P, Jarrousse B, Généreau T, Léon A. Lack of superiority of corticosteroids plus pulse cyclophosphamide and plasma exchanges to corticosteroids plus pulse cyclophosphamide in the treatment of polyarteritis nodosa and Churg-Strauss syndrome with poor prognostic factors. A prospective, randomized trial in 62 patients. Arthritis Rheum (in press), 1995.
24. Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, Noël LH, Trépo C. Polyarteritis nodosa related to hepatitis B virus: A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 74: 238-53, 1995.
25. Guillevin L, Lhote F, Gallais V, Jarrousse B, Royer I, Gayraud M, Bénichou J. Gastrointestinal tract involvement in polyarteritis nodosa and Churg-Strauss syndrome. Ann Méd Interne (Paris) 146: 260-67, 1995.
26. Guillevin L, Lhote F, Sauvaget F, Deblois P, Rossi F, Levallois D, Pourrat J, Christoforov B, Trépo C. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 53: 3:34-37, 1994.
27. Guillevin L, Merrouche Y, Gayraud M. Périartérite noueuse liée au virus de l'hépatite B. Détermination d'une stratégie thérapeutique nouvelle: 13 observations. Presse Med 1988: 1522-26, 1988.
28. Guillevin L, Visser H, Noël LH, Pourrat J, Vernier I, Gayraud M, Oksman F, Lesavre P. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and withoul hepatitis B virus infection and Churg-Strauss syndrome - 62 patients. J Rheumatol 20: 1345-49, 1993.
29. Haas C, Geneau C, Odinot JM, De JC, Lavner M, Lowenstein W, Choubrac P, Durand H. Angéïte allergique et granulomateuse de Churg et Strauss. Une étude rétrospective de 16 cas. Ann Méd Interne (Paris) 142: 335-42, 1991.
30. Hoffman G, Kerr G, Leavitt R, Hallahan C, Lebovics R, Travis W, Rottem M. Wegener's granulomatosis: An analysis of 158 patients. Ann Intern Med 116: 488-98, 1992.
31. Jarrousse B, Guillevin L, Bindi P, Hachulla E, LeClerc P, Gilson B, Remy P, Rossert J, Jacquot C. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 11: 615-21, 1993.
32. Jennette JC, Falk RJ. Disease associations and pathogenic role of antineutrophil cytoplasmic autoantibodies in vasculitis. Curr Opin Rheumatol 4: 9-15, 1992.
33. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187-92, 1994.
34. Kallenberg CG, Mulder AH, Tervaert JW. Antineutrophil cytoplasmic antibodies: A still-growing class of autoantibodies in inflammatory disorders. Am J Med 93: 675-82, 1992.
35. Kaplan E, Meier P. Nonparametric estimation for incomplete information. J Ann Stat Assoc 53: 457-81, 1958.
36. Leib E, Restivo C, Paulus H. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 67: 941-47, 1979.
37. Lhote F, Guillevin L, Leon A, Bussel A, Lok C, Sobel A, Simon P. Complications of plasma exchange in the treatment of polyarteritis nodosa and Churg-Strauss angiitis and the contribution of adjuvant immunosuppressive therapy: A randomized trial in 72 patients. Artif Organs 12: 27-33, 1988.
38. Lightfoot RW Jr, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ, Arend WP, Calabrese LH, Leavitt RY, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33: 1088-93, 1990.
39. Luqmani RA, Watts RA, Scott DG, Bacon PA. Treatment of vasculitis in rheumatoid arthritis. Ann Méd Interne (Paris) 145: 566-76, 1994.
40. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, et al. The American College of Rheumatology 1990 criteria for the classification of ChurgStrauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33: 1094-1100, 1990.
41. McMahon BJ, Heyward WL, Templin DW, Clement D, Lanier AP. Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long-term follow-up. Hepatology 9: 97-101, 1989.
42. Parangi S, Oz MC, Blume RS, Bixon R, Laffey KJ, Perzin KH, Buda JA, Markowitz AM, Nowygrod R. Hepatobiliary complications of polyarteritis nodosa. Arch Surg 126: 909-12, 1991.
43. Peto R, Pike M, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. II. Analysis and examples. Br J Cancer 35: 1-39, 1977.
44. Scott D, Bacon P, Elliott P, Tribe C, Wallington T. Systemic vasculitis in a district general hospital 1972-1980: Clinical and laboratory features, classification and prognosis in 80 cases. Q J Med 51: 292-311, 1982.
45. Trépo C, Ouzan D, Delmont J, Tremisi P. Supériorité d'un nouveau traitement curateur des périartérites noueueses induites par le virus de l'hépatite B grâce à l'association corticothérapie brève, vidarabine et échanges plasmatiques. Presse Med 17: 1527-31, 1988.
46. Valente R, Conn D. Influence of pathogenesis on therapeutic choices in systemic vasculitis. Ann Méd Interne (Paris) 145: 517-22, 1994.